Clinical Trials
15 trialsNCT04591431 2023-10-03
ROME
Fondazione per la Medicina Personalizzata
Phase 2 Unknown
NCT03805399 2022-08-10
FUTURE
Fudan University
Phase 1/2 Unknown
NCT04355858 2022-07-26
MULAN
Fudan University
Phase 2 Unknown
NCT05429684 2022-06-23
Precise Therapy for Refractory HER2 Positive Advanced Breast Cancer
First Affiliated Hospital Xi'an Jiaotong University
Phase 3 Unknown
NCT04212702 2021-01-12
ESR1 Mutations in Asian ER+ Metastatic Breast Cancer on Hormonal Therapy-based Treatments
National Taiwan University Hospital
Unknown
NCT02109913 2019-10-14
Analysis of Tumor Tissue and Circulating Genetic Material in the Blood to Obtain Further Insight in the Effectiveness of Everolimus When Combined With Exemestane
Amsterdam UMC, location VUmc
Phase NA Unknown
NCT01283789 2017-02-08
Lapatinib and RAD-001 for HER2 Positive Metastatic Breast Cancer
University of Kansas Medical Center
Phase 2 Unknown
NCT00499603 2016-11-01
Paclitaxel Followed by FEC Versus Paclitaxel and RAD001 Followed by FEC In Women With Breast Cancer
M.D. Anderson Cancer Center
Phase 2 Unknown
NCT02404051 2016-06-15
FEVEX
Consorzio Oncotech
Phase 3 Unknown
NCT02616848 2015-11-30
Safety and Tolerability of Everolimus in Combination With Eribulin in Triple-negative Breast Cancers
Istituti Ospitalieri di Cremona
Phase 1 Unknown
NCT02313051 2014-12-09
MIRACLE
ChineseAMS
Phase 2 Unknown
NCT02025712 2014-01-01
Exemestane Plus Everolimus for Hormone-receptor Positive Metastatic Breast Cancer
Organisation for Oncology and Translational Research
Phase 2 Unknown
NCT00466102 2012-08-30
RADAR
GBG Forschungs GmbH
Phase 2 Unknown
NCT01088893 2012-05-24
Everolimus in Breast Cancer Patients After Pre-operative Chemotherapy
Organisation for Oncology and Translational Research
Phase 2 Unknown
NCT00930475 2011-01-26
Everolimus (RAD001) and Carboplatin in Pretreated Metastatic Breast Cancer
Charite University, Berlin, Germany
Phase 1/2 Unknown